Drug Profile
Research programme: protein kinase C alpha inhibitors - Clinical Value Corporation
Alternative Names: GAP-107B8; PhGα1; TIM-10Latest Information Update: 28 Feb 2014
Price :
$50
*
At a glance
- Originator PharmaGap
- Developer PharmaGap; Queens University
- Class Antineoplastics; Peptides
- Mechanism of Action Protein kinase C-alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bladder cancer; Hypertension; Ovarian cancer; Solid tumours
Most Recent Events
- 04 Feb 2013 Discontinued - Preclinical for Bladder cancer in Canada (Intravesicular)
- 04 Feb 2013 Discontinued - Preclinical for Ovarian cancer in Canada (Intraperitoneal)
- 04 Feb 2013 Discontinued - Preclinical for Solid tumours in Canada (Intraperitoneal)